PL361807A1 - Stosowanie podstawionych pochodnych imidazo/1,2-a/pirydyn-,-pirymidyn-i-pirazyn-3-yloamin do wytwarzania leków dla inhibitowania NO-syntazy - Google Patents

Stosowanie podstawionych pochodnych imidazo/1,2-a/pirydyn-,-pirymidyn-i-pirazyn-3-yloamin do wytwarzania leków dla inhibitowania NO-syntazy

Info

Publication number
PL361807A1
PL361807A1 PL36180701A PL36180701A PL361807A1 PL 361807 A1 PL361807 A1 PL 361807A1 PL 36180701 A PL36180701 A PL 36180701A PL 36180701 A PL36180701 A PL 36180701A PL 361807 A1 PL361807 A1 PL 361807A1
Authority
PL
Poland
Prior art keywords
imidazo
pyrazine
pyrimidine
pyridine
nos
Prior art date
Application number
PL36180701A
Other languages
English (en)
Inventor
Bernd Sundermann
Corinna Maul
Hagen-Heinrich Hennies
Johannes Schneider
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7659598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL361807(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL361807A1 publication Critical patent/PL361807A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
PL36180701A 2000-10-13 2001-10-10 Stosowanie podstawionych pochodnych imidazo/1,2-a/pirydyn-,-pirymidyn-i-pirazyn-3-yloamin do wytwarzania leków dla inhibitowania NO-syntazy PL361807A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050663A DE10050663A1 (de) 2000-10-13 2000-10-13 Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
PCT/EP2001/011701 WO2002030428A1 (de) 2000-10-13 2001-10-10 Verwendung von substituierten imidazo[1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung

Publications (1)

Publication Number Publication Date
PL361807A1 true PL361807A1 (pl) 2004-10-04

Family

ID=7659598

Family Applications (1)

Application Number Title Priority Date Filing Date
PL36180701A PL361807A1 (pl) 2000-10-13 2001-10-10 Stosowanie podstawionych pochodnych imidazo/1,2-a/pirydyn-,-pirymidyn-i-pirazyn-3-yloamin do wytwarzania leków dla inhibitowania NO-syntazy

Country Status (17)

Country Link
US (1) US20040023972A1 (pl)
EP (1) EP1326613B2 (pl)
JP (1) JP2004510820A (pl)
AT (1) ATE268179T1 (pl)
AU (2) AU2001291893B9 (pl)
CA (1) CA2425672A1 (pl)
DE (2) DE10050663A1 (pl)
DK (1) DK1326613T4 (pl)
ES (1) ES2220810T5 (pl)
HU (1) HUP0303350A3 (pl)
MX (1) MXPA03003200A (pl)
NZ (1) NZ525779A (pl)
PL (1) PL361807A1 (pl)
PT (1) PT1326613E (pl)
SI (1) SI1326613T2 (pl)
TR (1) TR200401545T4 (pl)
WO (1) WO2002030428A1 (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10117184A1 (de) * 2001-04-05 2002-10-17 Gruenenthal Gmbh Substituierte Imidazol[1,2-a]-pyridin-3-yl-amid- und -aminverbindungen
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
DE10132726A1 (de) * 2001-07-05 2003-02-27 Gruenenthal Gmbh Verwendung von substituierten gamma-Lactonverbindungen als Arzneimittel
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
DE10240735A1 (de) * 2002-08-29 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von Modulatoren der NO-Signalkaskade und pharmazeutische Zusammensetzung
AU2003270489A1 (en) 2002-09-09 2004-03-29 Cellular Genomics, Inc. 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
WO2005046559A2 (en) 2003-11-06 2005-05-26 Lifescan, Inc. Drug delivery pen with event notification means
DE102004021716A1 (de) * 2004-04-30 2005-12-01 Grünenthal GmbH Substituierte Imidazo[1,2-a]pyridin-Verbindungen und Arzneimittel enthaltend substituierte Imidazo[1,2-a]pyridin-Verbindungen
DE602005013085D1 (de) * 2004-06-09 2009-04-16 Oncalis Ag Proteinkinaseinhibitoren
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
US7923041B2 (en) * 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
AU2006247118A1 (en) * 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
TW200800213A (en) * 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
MX2008008152A (es) 2005-12-23 2008-09-12 Ariad Pharma Inc Compuestos heterociclicos biciclicos.
JP2009538877A (ja) * 2006-05-31 2009-11-12 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピラジン化合物
DE102006028862A1 (de) * 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008016648A2 (en) * 2006-08-01 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
KR101410453B1 (ko) * 2006-08-02 2014-06-27 싸이토키네틱스, 인코포레이티드 소정의 화학 물질, 조성물 및 방법
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
DE102006048728A1 (de) * 2006-10-16 2008-04-17 Merck Patent Gmbh 3-Amino-imidazo{1,2-a]pyridinderivate
EP1964840A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridines and their use as pharmaceuticals
US20080249305A1 (en) * 2007-03-27 2008-10-09 Calderwood David J Novel imidazole based heterocycles
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
WO2008134553A1 (en) * 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
GB0708188D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
DE102007048716A1 (de) * 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo[1,2-a]pyrimidinderivate
EP2217069A4 (en) * 2007-11-09 2012-03-14 Salk Inst For Biological Studi INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
CN101910131B (zh) 2007-11-16 2014-04-23 里格尔药品股份有限公司 甲酰胺、磺酰胺和胺化合物及其使用方法
WO2009076631A1 (en) 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
CA2714414A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
JP5658138B2 (ja) 2008-04-23 2015-01-21 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害の処置のためのカルボキサミド化合物
WO2010032195A1 (en) 2008-09-16 2010-03-25 Csir Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors
TWI478922B (zh) 2008-12-08 2015-04-01 Gilead Connenticut Inc 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
US20120263646A1 (en) * 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US9562056B2 (en) 2010-03-11 2017-02-07 Gilead Connecticut, Inc. Imidazopyridines Syk inhibitors
CA2807230A1 (en) 2010-08-03 2012-02-09 The Regents Of The University Of California Compounds and compositions for mitigating tissue damage and lethality
JP6145946B2 (ja) 2011-07-13 2017-06-14 サイトキネティックス， インコーポレイテッド 併用ａｌｓ療法
WO2013071272A1 (en) * 2011-11-11 2013-05-16 Intellikine, Llc Kinase inhibitor polymorphs
WO2014021383A1 (ja) 2012-07-31 2014-02-06 協和発酵キリン株式会社 縮環複素環化合物
WO2014151529A1 (en) * 2013-03-15 2014-09-25 The Regents Of The University Of California Therapeutic agents and methods for the treatment of dna repair deficiency disorders
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
US20160168155A1 (en) 2013-07-30 2016-06-16 Gilead Connecticut, Inc. Polymorph of syk inhibitors
WO2015084992A1 (en) 2013-12-04 2015-06-11 Gilead Sciences, Inc. Methods for treating cancers
UY35898A (es) 2013-12-23 2015-07-31 Gilead Sciences Inc ?compuestos inhibidores de syk y composiciones que los comprenden?.
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
ME03580B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
ES2672797T3 (es) 2014-02-13 2018-06-18 Incyte Corporation Ciclopropilaminas como inhibidores de LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CA2939082C (en) 2014-02-13 2022-06-07 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
JP6310144B2 (ja) 2014-07-14 2018-04-18 ギリアード サイエンシーズ， インコーポレイテッド がんを処置するための組み合わせ
HUE057702T2 (hu) 2014-08-29 2022-05-28 Chdi Foundation Inc Szondák huntingtin fehérje képalkotáshoz
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
MX2018012901A (es) 2016-04-22 2019-06-06 Incyte Corp Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
CN115028640A (zh) 2017-08-25 2022-09-09 吉利德科学公司 Syk抑制剂的多晶型物
WO2019070943A1 (en) * 2017-10-04 2019-04-11 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
JP2022521413A (ja) 2019-02-22 2022-04-07 クロノス バイオ インコーポレイテッド Ｓｙｋ阻害剤としての縮合ピラジンの固体形態

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507294A (en) * 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
DE3269604D1 (en) * 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
GB8415540D0 (en) * 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
FR2638161B1 (fr) * 1988-10-24 1991-01-11 Centre Nat Rech Scient Nouvelles benzoyl-2 imidazo (1,2-a) pyridines et leurs sels, leur procede de preparation, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
MX22406A (es) † 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
IE904346A1 (en) † 1989-12-04 1991-06-05 Searle & Co IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF¹NEUROTOXIC INJURY
US5562921A (en) * 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
WO1996033195A1 (fr) * 1995-04-21 1996-10-24 Shinnippon Pharmaceutical Inc. IMIDAZO[1,2-a]PYRIDINES DE FUSION
AU6691798A (en) † 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
DE50006419D1 (de) † 1999-07-02 2004-06-17 Siemens Ag Verfahren zum überwachen einer mit luftüberschuss betreibbaren brennkraftmaschine
DE19948434A1 (de) * 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
DE10019714A1 (de) † 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
AU2001270297A1 (en) * 2000-06-30 2002-01-14 Neurogen Corporation 2-phenylimidazo(1,2-a)pyridine derivatives: a new class of gaba brain receptor ligands
DE10246890A1 (de) * 2002-10-08 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-alpyridin-3-yl-methylamine
DE10247269A1 (de) * 2002-10-10 2004-04-22 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine

Also Published As

Publication number Publication date
ES2220810T3 (es) 2004-12-16
TR200401545T4 (tr) 2004-08-23
SI1326613T1 (en) 2004-10-31
AU9189301A (en) 2002-04-22
PT1326613E (pt) 2004-10-29
EP1326613A1 (de) 2003-07-16
EP1326613B1 (de) 2004-06-02
JP2004510820A (ja) 2004-04-08
ES2220810T5 (es) 2007-12-01
US20040023972A1 (en) 2004-02-05
WO2002030428A1 (de) 2002-04-18
CA2425672A1 (en) 2003-04-11
AU2001291893B9 (en) 2006-11-09
HUP0303350A3 (en) 2006-02-28
DK1326613T4 (da) 2007-09-03
DK1326613T3 (da) 2004-10-11
SI1326613T2 (sl) 2007-08-31
AU2001291893B2 (en) 2006-05-18
ATE268179T1 (de) 2004-06-15
AU2001291893B8 (en) 2006-06-15
NZ525779A (en) 2005-01-28
EP1326613B2 (de) 2007-04-18
DE10050663A1 (de) 2002-04-18
HUP0303350A2 (hu) 2004-01-28
DE50102490D1 (de) 2004-07-08
MXPA03003200A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
PL361807A1 (pl) Stosowanie podstawionych pochodnych imidazo/1,2-a/pirydyn-,-pirymidyn-i-pirazyn-3-yloamin do wytwarzania leków dla inhibitowania NO-syntazy
TWI255807B (en) Therapeutic agents
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
WO2005011653A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
CA2284732A1 (en) Analogs of cocaine
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
IL133585A0 (en) Soluble prodrugs of paclitaxel
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
HUP0203437A3 (en) Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2005056524A3 (en) Therapeutic agents useful for treating pain
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
MXPA04004732A (es) Composiciones y estuches que comprenden un compuesto definido de boro, metodos para prepararlas y uso y administracion de las mismas.
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
WO2001007418A3 (en) Ceramide analogs, process for their preparation and their use as antitumor agents
HUP0301906A2 (en) Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity
UA66751C2 (en) Benzamides as medicament for treatment of neurodegenerative state, a method for the preparation thereof (variants), pharnaceutical composition for treatment of neurodegenerative states and a method for treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)